[{"id":"d073f301-e372-41e1-b809-81372f91b045","acronym":"","url":"https://clinicaltrials.gov/study/NCT02581878","created_at":"2021-01-18T12:31:16.901Z","updated_at":"2025-02-25T17:08:24.762Z","phase":"Phase 1","brief_title":"Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT02581878","lead_sponsor":"Bayer","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epratuzumab-thorium-227 (BAY1862864)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 11/20/2015","start_date":" 11/20/2015","primary_txt":" Primary completion: 11/11/2019","primary_completion_date":" 11/11/2019","study_txt":" Completion: 11/26/2019","study_completion_date":" 11/26/2019","last_update_posted":"2020-11-25"}]